Introduction
Guanidino compounds are small, water soluble, basic compounds present in high concentrations in the serum and urine of uremic patients like urea, 1,2 but they differ in from urea in their kinetic behavior on intradialysis. 3 A number of the compounds are reactive species and are labeled as uremic toxins. Methylguanidine (MG) is reported to be involved with uremic polyneuropathy found in uremia. 4 Guanidinosuccinic acid may cause uremic bleeding diathesis and could be responsible for uremic encephalopathy. 5 guanidinosuccinic acid (GSA), MG and guanidine (G) have been found to cause generalized seizures after intracere broventricular administration in mice. 6, 7 The concentration of guanidinoacetic acid (GAA) in plasma and urine is high in patients with guanidine acetate methyltransferase deficiency 8, 9 and the concentration of GSA is low in cirrhotic patients. 10 The identification and determination of guanidino compounds in the biological fluids have clinical importance.
For the determination of guanidino compounds, high performance liquid chromatography (HPLC) combined with UV detection has been used, 11 but for sensitive detection, pre or post column derivatization is carried out for HPLC determinations. The reagents used for the derivatization are mainly ninhydrin, 12, 13 benzoin, 9, 14, 15 furoin, 16 anisoin, 17 9,10-phenanthrequinone, 18 9,10-phenanthrequinone-3-sulfonate 19 and 2,2′-pyridoin. 20 Benzoin has also been used as a pre capillary derivatization reagent for guanidino compounds using micellar electrokinetic capillary chromatography. 21 The required sensitivity is achieved using HPLC but HPLC suffers from the problem of safe disposal of used solvents.
Capillary gas chromatography (GC) has high potential for the separation of sufficiently volatile and thermally stable organic compounds. GC involves relatively less expensive equipment with less running cost and short analysis time. The guanidino compounds are not adequately volatile to elute and separate from the GC column, but have been converted to a volatile product by reaction with hexafluoroacetylacetone 22 or with the use of two derivatizing reagents; either hexafluoroacetylacetone and trimethylsilyltrifluoroacetamide, 23, 24 hexafluoroacetylacetone and trifluoroacetic anhydride 25 or hexafluoroacetylacetone and pentafluorobenzyl bromide. 26 The first reagent has been used to bind guanidino group and another to carboxylic acid. A significant improvement in the chromatography is reported using two derivatizing reagents. 23 However the determination has been carried out for a limited number of guanidino compounds (two compounds).
Methylglyoxal and glyoxal are known to be present in the biological fluids of uremic patients. 27 They are reported to react with guanidino compounds in proteins and modify arginine residues. [28] [29] [30] [31] [32] [33] The reactions are reported to occur at physiological concentrations. GC elution of the guanidino compounds: G, MG, GAA, guanidinopropionic acid (GPA), ganidinobutyric acid (GBA) and GSA is possible after derivatization with glyoxal. 34 The imidazolone compounds formed contain free carboxylic acid group (Fig. 1) . Ethyl chloroformate (ECF) is reported to react with carboxylic acid and imino groups in an aqueous medium in alkaline solution (pH 9) to form ester and carbamate derivatives. [35] [36] [37] [38] [39] The present work examines the use of the two reagents glyoxal and ECF for suitable derivatization from an aqueous medium to improve sensitivity for GC 2013 © The Japan Society for Analytical Chemistry † To whom correspondence should be addressed. E-mail: subhan_majidano@yahoo.com Gas chromatographic (GC) method has been developed for the determination of the guanidino compounds: guanidine (G), methylguanidine (MG), guanidinoacetic acid (GAA), guanidinopropionic acid (GPA), guanidinobutyric acid (GBA) and guanidinosuccinic acid (GSA) was carried out after precolumn derivatization with glyoxal and ethyl chloroformate from the column HP-5 (30 m × 0.32 mm i.d.) at 90 C for 3 min, followed by a heating rate 25 C/min up to 260 C with a nitrogen flow rate of 2 ml/min. Detection was by FID. The linear calibrations were obtained within 0.1 -20.0 μmol/L, with limits of detection (LODs) within 0.014 -0.024 μmol/L. The separation and derivatization was repeatable (n = 6) with relative standard deviations (RSD) within 0.8 -1.9% in retention time and 0.5 -1.8% in peak height/peak area. A number of additives and amino acids did not affect the determination. The method was applied for the determination of guanidino compounds from the serum and urine of 9 healthy volunteers and 8 uremic patients and the amounts found were in the range 0.08 -0. determination of the guanidino compounds. The second derivatization with trimethyl silyltrifluoroacetamide 23 requires a non aqueous medium, where a second derivatization with ECF could be carried out in an aqueous medium. 36 The conditions for the double derivatization, solvent extraction, GC elution and separation are examined for the quantitative determination of guanidino compounds from biological fluids.
Gas Chromatographic Analysis of Guanidino Compounds in

Experimental
Chemicals and solutions
The compounds G, MG, GAA, GPA (Sigma Loius, USA), GBA (Sigma, Switzerland), GSA (Sigma GmbH, Germany), ECF, glyoxal (40%) (Fluka, Switzerland), and methanol (RDH, Germany) were used. Guaranteed reagent grade hydrochloric acid (37%), potassium chloride, acetic acid, sodium acetate, ammonium acetate, sodium tetraborate, boric acid, sodium bicarbonate, sodium carbonate, ammonium chloride and ammonia solution were obtained from E-Merck, Germany.
Stock solutions of guanidino compounds containing 1000 μmol/L were prepared in water containing a few drops of hydrochloric acid (1 M). Further solutions were prepared by appropriate dilution. The derivatizing reagent glyoxal (2%) was prepared in methanol. Buffer solutions (0.1 M) between pH 1 -10 at unit intervals were prepared from the following: pH 1 and 2 were prepared from HCl (0.1 M) by dilution with KCl (0.1 M), acetic acid-sodium acetate (pH 3 -6), ammonium acetate (pH 7), boric acid-sodium tetraborate (pH 7.5 -8.5), sodium bicarbonate-sodium carbonate (pH 9) and ammonium chloride-ammonia (pH 10).
Equipment
The pH measurements were made with an Orion 420A pH meter (Orion Research, Inc., Boston, USA) with combined glass electrode and reference internal electrode. GC-FID studies were carried out on an Agilent Model 6890 network GC system interfaced with flame ionization detection (FID) and split injector (Agilent Technologies, Santa Clara, CA), hydrogen generator (Parker Balston, Ananlytical Gas system, H2-90, Parker Hannifin, Havorhill, MA), and using pure nitrogen 
Analytical procedure
Ammonium acetate buffer pH 7 (0.2 ml) and glyoxal (2% in methanol v/v) (0.2 ml) were added to the solution (0.1 -1.0 ml) containing guanidino compounds (0.1 -20.0 μmol/L). The contents were warmed on water bath at 80 C for 20 min and allowed to cool at room temperature for 10 min. To this solution was added 0.2 ml of solvent system (acetonitrile-watermethanol-pyridine, 42:42:8:8), carbonate buffer pH 9 (0.2 ml) and ECF (0.2 ml) and the contents were sonicated for 15 min. Chloroform (1 ml) was added and the contents were mixed well. The layers were allowed to separate and an aliquot of organic layer was transferred to a screw capped sample vial. The extract (1 μl) was injected on the GC with HP-5 column with a temperature program 90 C for 3 min, followed by an increase in temperature at a rate of 25 C/min up to 260 C. The nitrogen flow rate was 2 ml/min with split ratio 10:1. Injector and detector temperatures were fixed at 270 and 280 C, respectively. The flow rates for FID were fixed as follows; nitrogen 45 ml/min, hydrogen 40 ml/min and air 450 ml/min.
Determination of guanidino compounds from serum
The blood samples (2 ml) collected from healthy volunteers or uremic patients were kept at room temperature (30 C) for 1 h and centrifuged at 3000g for 30 min. The supernatant layer of serum (1.0 ml) was separated, and was then added 1.0 ml of methanol. The contents were mixed well and centrifuged at 3000g for 20 min. The supernatant layer was collected and 0.5 ml of the solution was transferred to a screw-capped sample vial and was processed as analytical procedure. The quantitation was carried out from the linear regression equation Y = ax + b derived from external calibration curve.
Determination of guanidino compounds from spiked serum sample
Blood samples (2 ml) collected from healthy volunteers and uremic patients were processed as described as above. Two portions of 0.5 ml were taken from each after deproteinization with methanol and to one portion was added a mixture of guanidino compounds (0.3 ml; 6.0 μmol/L each), then both the solutions were processed as analytical procedure.
The quantitation was made from external calibration curve and from the increase in the response with added standards.
Determination of guanidino compounds from urine
Urine samples (2 ml) collected from healthy volunteers and uremic patients were mixed with methanol (2 ml). The mixture was centrifuged at 3000g for 30 min. Clear deproteinized urine sample (2 ml) was diluted to 5 ml with deionized water and 0.5 ml of the solution was processed as analytical procedure. The quantitation was carried out from external calibration curve.
Determination of guanidino compounds from spiked urine sample
Urine sample (2 ml) collected from healthy volunteers and uremic patients were processed as described above. Two portions of 0.5 ml were taken from each after deproteinization with methanol and to one portion was added a mixture of guanidino compounds (0.3 ml; 6.0 μmol/L each), then both the solutions were processed as analytical procedure.
Repeatability of the derivatization, solvent extraction and quantitation was measured by the same person on the same day (n = 4) and different day (n = 4) with the concentration range 0.5 -0.9 μmol/L of each guanidino compound. The responses were measured in terms of retention times and peak height/peak area.
Blood and urine samples of uremic patients were collected with patients' verbal consent from the medical wards at Liaquat University of Medical and Health Sciences Hospital in Jamshoro and Hyderabad. The blood samples were collected in sterilized EDTA tubes by vein puncture and morning urine samples were collected in clean plastic bottles. The blood and urine samples of healthy volunteers who had not taken any medicine for at least one week were collected from students and employees of the Institute of Advanced Research Studies in Chemical Sciences, University of Sindh, Jamshoro, Sindh, Pakistan. The samples were collected with verbal consent. The uremic patients and healthy volunteers were informed about the objectives of the project. The collected samples were quickly analyzed as received.
Results and Discussion
Derivatization and GC elution
The guanidino compounds did not elute from the GC column but eluted as derivatives of glyoxal. 34 In order to increase sensitivity of the determination of guanidino compounds, a second derivatization with ECF was examined to bind to a carboxylic acid group. An increase in sensitivity (peak height/peak area) within 30 -40% was observed on second derivatization as compared to the derivatization with only glyoxal. It was therefore the conditions for the second derivatization with ECF after glyoxal were examined and optimized.
The effect of reaction conditions was examined on the analysis in sequence. The pH, amount of derivatizing reagent added per analysis, solvent of reaction medium, effect of reaction time and order of addition of the reagents on derivatization were examined. The conditions that produced the maximum response (average peak height/peak area) were considered as optimal. The effect of pH was examined within pH 1 -10 at unit intervals. The reaction of glyoxal with guanidino compounds was as previously observed maximum at pH 7, but the second derivatization with ECF was observed maximum at pH 9 and carbonate buffer was used as reported for related compounds. 36 The volume of carbonate buffer added per analysis was varied from 0.2 to 1.0 ml at an interval of 0.2 ml and the change in the volume of buffer added did not affect the average response (n = 4) and the volume of buffer added was fixed at 0.2 ml. The additions of derivatizing reagents were not critical until excess of the reagents were present during derivatization. The addition of 0.2 ml of 2% v/v of glyoxal was adequate for first derivatization as observed earlier, 34 but the variation in the addition of pure ECF was examined within 0.1 -1.0 ml at an interval of 0.1 ml and the addition of 0.2 ml was considered as optimal and was used. The solvent system is reported to have influence on the derivatization with ECF, 36 therefore the addition of the methanol, acetonitrile and solvent system (acetonitrilewater-methanol-pyridine, 42:42:8:8) to the reaction mixture was examined after first derivatization with glyoxal. The addition of (acetonitrile-water-methanol-pyridine, 42:42:8:8) solvent system was selected as reported for similar reactions. 36 The reaction mixture was sonicated for 5 -30 min with an interval of 5 min after the addition of the reagents for second derivatization. The sonication for 15 min was selected. The effect of order of the addition of the reagents: the solvent, buffer and ECF for second derivatization was examined, but no significant effect was observed. Chloroform, tertiary butanol, 1,2-dichloroethane and ethyl acetate were examined as solvent for the extraction of the derivatives.
Chloroform and 1,2-dichloroethane indicated a similar extraction efficiency, but chloroform was used as reported by other researchers. 36 The conditions for the GC elution and the separation of the guanidino compounds from the column HP-5 were examined. Different temperature elution programs and nitrogen flow rates were investigated. The initial temperature was varied from 80 -100 C for 1 to 4 min, followed by heating rate 10 -25 C/min up to 200 to 270 C with nitrogen flow rate 1 to 4 ml/min. The elution program with initial temperature 90 C for 3 min followed by the heating rate 25 C/min up to 260 C for 3 min, with a nitrogen flow rate of 2 ml/min gave better sensitivity with complete base line separation and was selected. The resolution factor (Rs) between adjacent peaks was observed >1.5 (Fig. 2) . The order of the elution of the compounds was (1) derivatizing reagents, (2) G, (3) MG, (4) GAA, (5) GPA, (6) GBA and (7) GSA. The elution of the compound followed natural order with increase in the retention time with an increase in the molecular mass within homologous series of guanidino compounds.
Repeatability of the derivatization and GC elution were examined in terms of retention time and peak height (n = 5); the relative standard deviations (RSDs) were obtained within 1.7 -2.3% and 1.2 -2.8%, respectively.
Quantitation
The linear calibration curves were constructed by recording average peak height (n = 4) versus concentration at the selected operating conditions. The linear calibrations were observed within 0. Table 1 ). The reproducibility of quantiation measured in the terms of peak height and retention times was examined at inter (n = 4) and intra (n = 4) days for all the six guanidino compounds at a concentration of 0.5 -0.9 μmol/L. The changes in peak height inter and intra day were observed with RSDs within 0.5 -1.0% and 0.9 -1.9%, respectively. The corresponding RSDs for retention times were 0.8 -1.6% and 1.6 -2.0%, respectively. The analysis of test mixtures (n = 4) of the guanidino compounds within calibration range was conducted with relative error within ±2.7%.
Effect of additives
The interfering effect of amino acids and pharmaceutical additives on the determination of guanidino compounds was examined.
The compounds glycine, serine, alanine, phenylalanine, glutamic acid, aspartic acid, ascorbic acid, glucose and fructose were added at twice the concentration of the guanidino compounds, and their effects on separation, retention time and peak height were examined. The average responses (n = 3) were compared to the standard solution of guanidino compounds. The presence of amino acids and the additives did not affect the determination with relative error within ±2.9%.
Sample analysis
The method was examined for the determination of guanidino compounds from the serum of healthy volunteers and uremic patients. Pre deproteinized serum was analyzed for the contents of the six guanidino compounds G, MG, GAA, GPA, GBA and GSA. At the same time blank serum samples were also prepared from the serum samples without the addition of derivatizing reagents, but the elution of the guanidino compounds was not detected (Fig. 3) . The identification of analytes was carried out by comparison of chromatographic retention times (tR) with those of standard guanidino compounds and by spiking each of the compounds in sequence. The amounts of guanidino compounds from the serum of nine healthy volunteers aged 17 -29 years were as follows; 0.15 -0.23 μmol/L for G, 0.21 -0.39 μmol/L for GAA, 0.08 -0.18 μmol/L for GPA, 0.10 -0.21 μmol/L for GBA and 0.29 -0.48 μmol/L for GSA with RSDs within 1.0 -3.0%. The amount for MG was below LOD ( Table 2 , Fig. 4) .
Similarly, the urine samples of these healthy volunteers indicated guanidino compounds in the range of 13.9 -16.0 μmol/L for G, 320 -345 μmol/L for GAA, 0.27 -0.39 μmol/L for GPA, 0.38 -0.45 μmol/L for GBA, below LOD -3.1 μmol/L MG, and 19.9 -25.0 μmol/L GSA with RSDs within 1.0 -4.2% (Table 2) . Table 2 Concentration (μmol/L) of guanidino compounds in serum and urine of healthy volunteers S3  S4  S5  S6  S7  S8  S9  S9   a   U1  U2  U3  U4  U5  U6  U7  U8  U9  U9   a   19F  23F  21M  20M  29F  21M  17M  20M  22F  19F  23F  21M  20M  29F  21M  17M  20M Table 1 Quantitative data of guanidino compounds by GC using glyoxal and ECF as derivatizing reagents The serum and urine samples of eight uremic patients aged 50 -61 years were also analyzed. The serum samples indicated concentrations μmol/L within 3.04 -4.90 for G, 2.03 -2.14 for MG, 3.04 -7.23 for GAA, 1.82 -2.39 for GPA, 1.96 -2.42 for GBA and 9.59 -13.88 for GSA with RSDs within 1.1 -3.5% (Table 3) . A serum sample from healthy volunteer and a sample from uremic patient were spiked with standards of G, MG, GAA, GBA, GPA and GSA and corresponding increase in the peak heights were observed without change in peak shape. This may indicate that matrix of deproteinized serum do not interfere with the derivatization, solvent extraction and GC determination of guanidino compounds. The recovery rates for G, MG, GAA, GPA, GBA and GSA from the spiked serum sample were calculated 99, 99, 97, 98, 98 and 96% with %RSDs of 2.4, 3.5, 3.4, 3.0, 2.0, 3.0, respectively.
The analysis of urine samples of uremic patients indicated the concentrations of guanidino compounds μmol/L within G 19.8 -23.6, MG 32.2 -38.2, GAA 382 -432, GPA 0.77 -0.96, GBA 3.0 -3.9 and GSA 121 -137 with RSD within 1.1 -3.5% (Table 3) . A urine sample of healthy volunteer and uremic patient was also spiked with the standards of guanidino compounds, the results obtained agreed with the observed values by external calibration (Tables 2 and 3 ) and the % recovery of G, MG, GAA, GPA, GBA and GSA from the spiked urine sample was calculated 97.5, 97.6, 99.5, 98.9, 94.4, and 97.8 with RSD within 1.0 -3.1% respectively. The result also indicated that the deproteinized urine matrix did not interfere the quantitative determination of the guanidino compounds.
The results of sample analysis for the guanidino compounds from serum and urine from healthy volunteers and uremic patients were compared with corresponding reported values. The results of the analysis in the serum of uremic patients agreed with reported values of Gatti and Gioia 16 and Kikuchi et al. 40 The results of analysis for urine samples of healthy volunteers also agree with reported values. 17 The developed analytical procedure was compared with reported GC methods. [22] [23] [24] [25] [26] The reported GC procedures required warming of 2 -3 h for derivatization with hexafluoroacetylacetone followed by silylation with suitable reagent, which may require non aqueous medium. In the present work first derivatization required warming for 20 min followed by second derivatization in aqueous medium with ECF. The reported GC procedures are for 1 to 2 guanidino compounds, but the present method reports the analysis of six guanidino compounds with GC elution time within 10 min. When compared with glyoxal, an improvement in peak shape has resulted by the use of two derivatizing reagents (glyoxal + ECF) and the derivatives eluted with lower carrier flow rate (2 ml/min) as compared to 3 ml/min using single reagent (glyoxal). An improvement in LOD and LOQ due to the use of two derivatizing reagents and the ease of derivatization with inexpensive chemicals are added advantages of the procedure.
Conclusion
A GC analytical procedure has been proposed for the determination of six guanidino compounds from deproteinized serum and urine samples. The method is based on derivatization with glyoxal and ECF in an aqueous organic solvent. The method indicated adequate sensitivity with LOD within 0.014 -0.024 μmol/L and linear calibration range within 0.1 -20 μmol/L for application to biological fluids. The procedure was 
